Terns Pharmaceuticals (NASDAQ:TERN) Stock Rating Lowered by Leerink Partners

Terns Pharmaceuticals (NASDAQ:TERN) was downgraded by research analysts at Leerink Partners from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.

Several other research analysts also recently commented on the company. Oppenheimer raised their price objective on Terns Pharmaceuticals from $28.00 to $58.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 9th. Wall Street Zen downgraded Terns Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Mizuho downgraded Terns Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 27th. HC Wainwright reiterated a “neutral” rating and set a $53.00 target price (down from $60.00) on shares of Terns Pharmaceuticals in a research report on Wednesday, March 25th. Finally, BMO Capital Markets cut Terns Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, March 26th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $56.30.

Terns Pharmaceuticals Price Performance

Terns Pharmaceuticals stock opened at $52.56 on Wednesday. Terns Pharmaceuticals has a one year low of $2.04 and a one year high of $53.19. The stock has a market capitalization of $6.07 billion, a PE ratio of -51.03 and a beta of -0.37. The business’s fifty day moving average is $44.41 and its 200 day moving average is $31.89.

Terns Pharmaceuticals (NASDAQ:TERN) last posted its earnings results on Thursday, April 2nd. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.06. As a group, sell-side analysts expect that Terns Pharmaceuticals will post -1.19 EPS for the current fiscal year.

Insider Activity at Terns Pharmaceuticals

In other Terns Pharmaceuticals news, insider Emil Kuriakose sold 942 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $52.75, for a total transaction of $49,690.50. Following the completion of the transaction, the insider owned 105,673 shares in the company, valued at $5,574,250.75. This trade represents a 0.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Amy L. Burroughs sold 68,749 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $37.07, for a total value of $2,548,525.43. Following the transaction, the chief executive officer owned 288,976 shares of the company’s stock, valued at $10,712,340.32. This represents a 19.22% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 98,857 shares of company stock valued at $3,850,896 in the last 90 days. 1.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Terns Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Terns Pharmaceuticals during the 4th quarter worth approximately $25,000. GAMMA Investing LLC lifted its stake in shares of Terns Pharmaceuticals by 762.4% during the 4th quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock worth $35,000 after acquiring an additional 770 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Terns Pharmaceuticals by 61.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,207 shares of the company’s stock worth $89,000 after acquiring an additional 841 shares during the last quarter. Vanguard Personalized Indexing Management LLC lifted its stake in shares of Terns Pharmaceuticals by 5.1% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 18,555 shares of the company’s stock worth $750,000 after acquiring an additional 906 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Terns Pharmaceuticals by 29.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,377 shares of the company’s stock worth $177,000 after acquiring an additional 994 shares during the last quarter. 98.26% of the stock is owned by institutional investors.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.